Somatic BRCA1 loss-of-function variants in advanced EOC confer PARPi sensitivity equivale...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BMA-BRCA1-SOMATIC-OVARIAN`
Type	Actionability
Status	reviewed 2026-04-27 \| pending_clinical_signoff \| actionability review required
Diseases	`DIS-OVARIAN`
Sources	`SRC-CIVIC` `SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Actionability Facts

Biomarker	`BIO-HRR-PANEL`
Variant	BRCA1 somatic loss-of-function
Disease	`DIS-OVARIAN`
ESCAT tier	IA
Recommended combinations	olaparib monotherapy maintenance, rucaparib monotherapy maintenance, olaparib + bevacizumab (PAOLA-1)
Evidence summary	Somatic BRCA1 loss-of-function variants in advanced EOC confer PARPi sensitivity equivalent to germline; olaparib 1L maintenance (SOLO1 included sBRCA in EU label) and rucaparib 3L+ are FDA/EMA-approved regardless of germline status. ESCAT IA / OncoKB Level 1.

Notes

Somatic-only finding does NOT trigger cascade family testing. Tumor NGS reveals; reflex germline testing recommended to clarify. Same drug menu as germline.

Used By

No reverse references found in the YAML corpus.